Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $43.00

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have received a consensus rating of “Moderate Buy” from the eleven brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $43.00.

A number of equities research analysts have issued reports on the stock. Wedbush increased their target price on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Chardan Capital restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Guggenheim reaffirmed a “buy” rating and issued a $60.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. The Goldman Sachs Group initiated coverage on Stoke Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $44.00 price objective for the company. Finally, Canaccord Genuity Group lowered their target price on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th.

Insider Activity

In related news, insider Barry Ticho sold 7,176 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04. Following the transaction, the insider owned 20,422 shares of the company’s stock, valued at approximately $593,054.88. This trade represents a 26.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the sale, the general counsel owned 18,086 shares of the company’s stock, valued at $541,675.70. This trade represents a 7.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 10,428 shares of company stock valued at $306,919. 9.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of STOK. Hussman Strategic Advisors Inc. bought a new stake in shares of Stoke Therapeutics during the 4th quarter worth $2,000,000. Baillie Gifford & Co. bought a new position in Stoke Therapeutics in the 4th quarter worth $7,837,000. Dimensional Fund Advisors LP raised its holdings in Stoke Therapeutics by 19.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company’s stock worth $32,229,000 after acquiring an additional 162,797 shares during the period. Candriam S.C.A. lifted its position in Stoke Therapeutics by 12.4% during the 1st quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock worth $16,346,000 after acquiring an additional 55,330 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in Stoke Therapeutics by 11.2% during the 1st quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock worth $52,456,000 after acquiring an additional 161,848 shares during the last quarter.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $32.23 on Tuesday. The stock has a market cap of $2.08 billion, a PE ratio of -9.65 and a beta of 1.20. Stoke Therapeutics has a fifty-two week low of $12.86 and a fifty-two week high of $40.22. The stock’s 50-day moving average is $30.49 and its two-hundred day moving average is $32.10.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The company had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. On average, equities research analysts anticipate that Stoke Therapeutics will post -3.5 earnings per share for the current year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.